Invention Grant
- Patent Title: Compounds inhibiting leucine-rich repeat kinase enzyme activity
-
Application No.: US15035255Application Date: 2014-11-10
-
Publication No.: US09809568B2Publication Date: 2017-11-07
- Inventor: Duane DeMong , Michael Miller , Hong Liu , Xing Dai , Thomas Greshock , Andrew Stamford , Ravi Nargund
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Keith D. MacMillan; John C. Todaro
- International Application: PCT/US2014/064726 WO 20141110
- International Announcement: WO2015/073344 WO 20150521
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D401/14 ; C07D231/56
Abstract:
The present invention is directed to substituted indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Public/Granted literature
- US20160289207A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY Public/Granted day:2016-10-06
Information query
